CTRI/2025/12/099000尚未招募不适用
Comparative Effectiveness of Combination of Second-line oral anti-diabetic treatment among the patients of Type-2 DM: A Prospective, Observational, Hospital-based Study in JA group of Hospital of Gajra raja medical college, Gwalior.
Dr Tribeni Debbarma1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2025年12月26日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- To evaluate the changes in Glycated Hemoglobin and body mass index from baseline, 3 months, 6 months and 9 months among sulfonyluraes, DPP 4 inhibitors and sglt 2c groups
研究概览
简要总结
This study aims to compare 3 groups of second line oral hypoglycaemic drugs which are dpp 4 inhibitors, sulfonylureas and sodium glucose cotransporter 2 inhibitors which among these drugs provide the best glycaemic control among the diabetic patients with a hbaic values between seven to 10 percentage.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)(—)
- 性别
- All
入选标准
- •• Diabetic patients with age group:18-65yrs • On Metformin Monotherapy for 3 months with inadequate glycemic control (HbA1c: 7-10% at baseline) will be given as an add-on therapy to Second-line drugs such as SUs (e.g.: glimepiride), DPP-4i (e.g.: Sitagliptin), SGLT-2i (e.g.: Dapagliflozin) as prescribed by treating physician.
- •• Patient willing to sign Informed and written consent.
排除标准
- •TYPE 1 DIABETES OR GESTATIONAL DIABETES, HISTORY OF INSULIN USE OR HISTORY OF OTHER INJECTABLE ANTI DIABETIC DRUG USE, SEVERE RENAL IMPAIREMENT WHICH IS EGFR LESS THAN 30ML PER MINUTE, SEVERE HEPATIC IMPAIREMENT, SEVERE CARDIOVASCULAR EVENTS, HISTORY OF DIABETIC KETOACIDOSIS, PREGNANCY OR LACTATION.
结局指标
主要结局
To evaluate the changes in Glycated Hemoglobin and body mass index from baseline, 3 months, 6 months and 9 months among sulfonyluraes, DPP 4 inhibitors and sglt 2c groups
时间窗: BASELINE, 3 MONTHS, 6 MONTHS AND 9 MONTHS
次要结局
- To Assess changes in Systolic BP & eGFR at Baseline, 3 months, 6 months & 9 months.(To Compare Adverse Events (e.g. Hypoglycemia, weight gain) caused among different treatment groups.)
研究者
Dr Tribeni Debbarma
Gajra Raja Medical College, Gwalior, M.P.
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)Type 2 DiabetesNCT07311551Bhavya Bhavya, MD112
尚未招募
不适用
Studying how well adding an h2 blocker works with an h1 blocker in treating chronic spontaneous urticariaCTRI/2025/10/096178Nabanita Das200
招募中
1 期
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes MellitusType 2 DiabetesNCT07374328Second Affiliated Hospital of Guangzhou Medical University240
进行中(未招募)
3 期
一项在二甲双胍单药或二甲双胍联合磺脲类药物治疗血糖控制不佳的中国 2 型糖尿病受试者中比较 BGM0504 注射液和司美格鲁肽注射液的有效性和安全性的随机、开放、阳性药平行对照的Ⅲ期临床研究本品拟用于 2 型糖尿病患者的治疗。CTR20244493537
尚未招募
不适用
Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose MetabolismNCT07263802Fondazione IRCCS Policlinico San Matteo di Pavia90
